For research use only. Not for therapeutic Use.
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity[1][2].
Oleclumab (10 mg/kg; ip; every 3 days for 4 doses) increases the proportion of activated CD8+ lymphocyte populations in the mouse Balb/c syngeneic CT26 colon cancer tumor model. And Oleclumab significantly inhibits tumor growth[2].
| Catalog Number | I043768 |
| CAS Number | 1803176-05-7 |
| Purity | ≥95% |
| Reference | [1]. Roy S Herbst, et al. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Apr 22;JCO2200227. [2]. Hay CM, et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology. 2016 Jul 11;5(8):e1208875. |
